Cell Therapy Global Market Report 2024 - By Size, Share, Demand, Growth Analysis, Forecast To 2033

"The new report published by The Business Research Company, titled ""Cell Therapy Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the cell therapy market size has grown rapidly in recent years. It will grow from $12.58 billion in 2023 to $14.72 billion in 2024 at a compound annual growth rate (CAGR) of 17.0%. The cell therapy market size is expected to see rapid growth in the next few years. It will grow to $25.86 billion in 2028 at a compound annual growth rate (CAGR) of 15.1%.

Download Free Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=3393&type=smp

The Soaring Prevalence Of Chronic Diseases Fuels Expansion In The Cell Therapy Market
The rising prevalence of chronic diseases aided the expansion of the cell therapy market. According to the US Centers for Disease Control and Prevention (CDC), chronic disease is a condition that lasts for one year or more, requires medical attention, limits daily activities, or both, and includes heart disease, cancer, diabetes, and Parkinson's disease. Stem cells can benefit patients suffering from spinal cord injuries, type 1 diabetes, Parkinson's disease (PD), heart disease, cancer, and osteoarthritis. For instance, according to the Center for Disease Control and Prevention report in 2021, due to poor nutrition and a lack of physical activity, 6 in 10 adults in the USA are suffering from a chronic disease, and 4 in 10 have two or more diseases. In December 2021, according to the International Diabetes Federation, a Belgium based health organization, about 537 million people (20-79 years old) will have diabetes. By 2030, there will be 643 million diabetics worldwide, and by 2045, there will be 783 million. Nearly one-half of all diabetics (240 million) go undiagnosed, and three out of every four diabetic adults live in low- and middle-income countries. According to the Parkinson's Foundation, in 2021, approximately 60,000 Americans will be diagnosed with PD each year, and 10 million individuals worldwide will suffer from this disease. After Alzheimer's, it is the second most prevalent neurological disease. The growing prevalence of chronic diseases increased the demand for cell therapies and contributed to the growth of the cell therapy market.

Strategic Partnerships And Acquisitions Drive Expansion In The Cell Therapy Market
Key market players are strategically partnering and collaborating to expand the company's product portfolio and geographical presence. For instance, in October 2021, Takeda, a Japan-based pharmaceutical company, acquired GammaDelta Therapeutics, a US-based company that offers cell therapies, to speed up the development of allogeneic T cell therapies for solid tumours. Furthermore, in June 2021, Charles River Laboratorie, a US-based pharmaceutical company, acquired Vigene Biosciences Inc., a US-based biotech company. With this acquisition, Charles River aims to expand its gene therapy capabilities, establish an end-to-end gene therapy solution in the US, and accelerate its long-term revenue and earnings growth potential.

The cell therapy market covered in this report is segmented -
1) By Technique: Stem Cell Therapy, Cell Vaccine, Adoptive Cell Transfer (ACT), Fibroblast Cell Therapy, Chondrocyte Cell Therapy
2) By Therapy Type: Allogeneic Therapies, Autologous Therapies
3) By Application: Oncology, Cardiovascular Disease (CVD), Orthopedic, Wound Healing, Other Applications

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=3393&type=discount

Major companies operating in the cell therapy market report are Celgene Corporation, JCR Pharmaceuticals Co. Ltd., Baxter Healthcare Corporation, Nipro Corp., Stempeutics Research Pvt. Ltd., Osiris Therapeutics Inc., Vericel Corporation, AlloSource, Anterogen Co. Ltd., Arteriocyte Medical Systems Inc., MediPost Co. Ltd., Pharmicell Co. Ltd., Corestem Inc., Stemedica Cell Technologies Inc., Adaptimmune Therapeutics plc, Mesoblast Ltd., Cell Medica Ltd., Cellerant Therapeutics Inc., Kolon TissueGene Inc., Tego Science Inc., Athersys Inc., 4D Molecular Therapeutics Inc., Abeona Therapeutics Inc., Forticell Bioscience Inc., Bone Therapeutics, Holostem Terapie Avanzate S.r.l, Fibrocell Science Inc., AlloCure Inc., TiGenix NV, Cells for Cells, AVROBIO Inc., Cellular Biomedicine Group Inc., Thermo Fisher Scientific Inc., Merck Co. & KGaA, Charles River Laboratories International Inc., Lonza Group Ltd., Catalent Inc.

Contents of the report:
1. Executive Summary
2. Cell Therapy Market Report Structure
3. Cell Therapy Market Trends And Strategies
4. Cell Therapy Market - Macro Economic Scenario
5. Cell Therapy Market Size And Growth
…..
27. Cell Therapy Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @
https://www.thebusinessresearchcompany.com/report/cells-therapy-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ"

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.